News

Blueberry Therapeutics commence Phase I-II clinical trial of lead product BB2603

Blueberry Therapeutics are pleased to announce they have dosed the first patient in a Phase I/II clinical trial of BB2603 in fungal infection of the skin and nail following successful regulatory and ethics approvals. The trial, which is a safety a...

Proveca raises £4m led by Catapult Ventures to launch children’s drug Sialanar in Europe and accelerate children’s medicines pipeline

Manchester, UK – 29th March 2017. Proveca, a European paediatric speciality pharmaceutical company, today announced that it has raised £4m to fund the commercial launch of Sialanar™ and the development and commercialisation...

Growing Chemistry CRO YProtech adds High Potency Capabilities

YProtech, the fast growing contract research organisation (CRO) focused on niche chemistry based services, has installed a high potency facility for the synthesis and manufacture of highly potent cytotoxins for applications in cancer treatment. T...

GM&C Life Sciences Fund Invests in YProTech High Value Chemistry Services

Alderley Park, Cheshire, UK – 6 October 2016. Catapult Ventures, managers of the GM&C Life Sciences Fund, today announced an investment in YProTech Ltd, a specialist high value chemistry services company based in Alderley Park, Cheshire....

2016 BioCap Pitching Competition Winner Announced

Bionow are delighted to announce The Research Network as the winner of the 2016 BioCap Company Pitching Competition. The Research Network, who are developing EmstoPA, a humanised antibody fragment for the treatment of bleeding complications in pa...

From our portfolio

Pronec

Pharmaceuticals

viewview our portfolio

Our Team

Nick Wright

CEO

view complete team

Contact us

Biohub
Alderley Park
Alderley Edge
Cheshire
SK10 4TG

Tel: 01625 344300

email